Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > The restart has started!
View:
Comment by scarlet1967 on Aug 22, 2023 7:16am
That will be helpful: "Part 4 (basket expansion): selected cancer type diagnosed with histologically or cytologically confirmed cancers, where TH1902 has been studied and/or showed activity (in Parts 1 to 3), that is refractory or resistant to standard therapies, and where current therapy is not considered to be providing benefit."
Comment by scarlet1967 on Aug 22, 2023 7:38am
Again to me the interesting part is 4! They plan was to enroll 6 new(as I understand it)patients in part 3 with the lower dose followed by 6 patients in part 4 on the higher dose now it seems those final 6 patients could include patients from previous enrolled patients which could only improve the odds...
Comment by scarlet1967 on Aug 22, 2023 8:27am
 Ignore the previous post this is what they said: "The amended study will be a modified 6+6 design with two different dosing regimens that are within the efficacious range for sudocetaxel zendusortide: 1.75 mg/kg on days 1, 8, and 15 of a 28-day cycle (similar to 210 mg/m2 every 3 weeks) and 2.5 mg/kg on the same schedule (similar to 300 mg/m2every 3 weeks). A minimum of six ...more  
Comment by Trogarzon on Aug 22, 2023 9:00am
So the reverse split in about one month amounts to nothing once again... a neutral event. Once again wrong move, no follow up with encouraging news, no institutional support... no plan and usual disaster as anticipated and warned againts without anyone listening overthere.
Comment by Trogarzon on Aug 22, 2023 9:41am
Honestly,I never saw a bunch of lousy no good people like this management team and BOD... it's an insult to intelligence.
Comment by Trogarzon on Aug 22, 2023 9:51am
This company is runned by morrons on a mission to failure. I am calling upon large shareholder to call a urgent meeting.
Comment by juniper88 on Aug 22, 2023 7:19am
That site always had "enrolling" on it.  Notice, the description doesn't even have the updated description.   This site simply is not updated (I have been monitoring it).  The clinicaltrials.org site was updated yesterday and it still says "Active, not recruiting"
Comment by scarlet1967 on Aug 22, 2023 7:27am
The part 3 and 4 are are new updates todsy as of yesterday there were not there also I happen to know they were enrolling/informing patients about the trial for a while but waited until their site to get updated. The government sites get updated always after the fact.
Comment by juniper88 on Aug 22, 2023 7:38am
Honestly, I hope you are right.  But it shows again that THTX has a serious communication issue.  Is that the press release they wanted to do yesterday?  Anyone who reads that press release and tries to watch the video just gets the "this video is private" message.  Which is pretty much how this company is run.  It makes them look like they are clueless.  In ...more  
Comment by juniper88 on Aug 22, 2023 7:58am
This is what part 4 states: Part 4 (basket expansion): selected cancer type diagnosed with histologically or       cytologically confirmed cancers, where TH1902 has been studied and/or showed activity (in       Parts 1 to 3), that is refractory or resistant to standard therapies, and where current       therapy is not considered to be providing ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities